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Abstract
Background: There is little evidence to support the management of severe COVID-19 patients.
Methods: To document this variation in practices, we performed an online survey (April 30–May 25, 2020) on
behalf of the European Society of Intensive Care Medicine (ESICM). A case vignette was sent to ESICM members.
Questions investigated practices for a previously healthy 39-year-old patient presenting with severe hypoxemia
from COVID-19 infection.
Results: A total of 1132 ICU specialists (response rate 20%) from 85 countries (12 regions) responded to the survey.
The survey provides information on the heterogeneity in patient’s management, more particularly regarding the
timing of ICU admission, the first line oxygenation strategy, optimization of management, and ventilatory settings in
case of refractory hypoxemia. Practices related to antibacterial, antiviral, and anti-inflammatory therapies are also
investigated.
Conclusions: There are important practice variations in the management of severe COVID-19 patients, including
differences at regional and individual levels. Large outcome studies based on multinational registries are warranted.
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Background
There is little evidence to support the optimal manage-
ment of severe COVID-19 patients [1, 2]. To document
whether there is a variation in practices, we performed
an online survey (April 30–May 25, 2020) on behalf of
ESICM.
Methods
In this online survey, a case vignette (https://www.sur-
veymonkey.com/r/F2FFC6S) was sent to ICU specialists
who are members of ESICM. Questions investigated
practices for a previously healthy 39-year-old patient
presenting with severe hypoxemia from COVID-19
infection (Table 1). The 85 participating countries were
grouped into 12 different regions [3]: continuous
variables are described as median (interquartile range
[IQR]) and are compared between groups using the
non-parametric Wilcoxon rank-sum test. Categorical
variables are described as frequency (percentages) and
are compared between groups using Fisher’s exact test.
Statistical analyses were performed with R statistical
software, version 3.4.3 (available online at http://www.r-
project.org/). A p value < 0.05 was considered
significant.
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Results
Response rate was 20% (N = 1132 intensive care (ICU)
specialists from 85 countries, including 1001 complete
answers). Respondents (median 45 years [IQR, 39–
53], 34% women) were from Middle Europe (25%),
South Europe (23%), the United Kingdom (UK) (12%),
South America (9%), North Europe (8.1%), Eastern
Europe (5.3%), Middle-East (5%), North America
(4.7%), Asia (3.3%), India (2.7%), Australia-New
Zealand (1.3%), or Africa (0.6%); 54% were living in a
large city (> 1 million inhabitants), and 55% were
working in university-affiliated hospitals. The median
Table 1 Distribution of the responses to the case vignette
Numbers (%) or median (interquartile ranges) Total, 1001 respondents
1. Admission to the ICU of a previously healthy 39-year-old man with severe COVID-19
Direct admission to the ICU 55%
Admission in an intermediate care unit 34.2%
Delayed admission to the ICU because of lack of bed 1.3%
Patient stays in the emergency department 0.8%
Patient admitted in the wards 8.8%
2. Initial oxygenation strategy
I increase the oxygen flow to 15 l/min keeping the face mask 24.2%
I change the mask for a Venturi mask 17.5%
I start CPAP or noninvasive ventilation 25.5%
I start high flow nasal oxygen 47.1%
I intubate the patient right away 7.4%
I add prone positioning on spontaneous breathing 37.9%
3. Optimizing oxygenation in a patient with a PF ratio of 84 4 h after intubation
I will give neuromuscular blockade for 24–48 h 50.9%
I increase and titrate PEEP to optimize recruitment 61.4%
I prone the patient immediately 73.2%
I am considering ECMO immediately 4.7%
Let us wait a little bit 9.9%
4. Regarding the initial antibiotics
All my patients receive a broad anti-bacterial agent 45.3%
I only give broad anti-bacterial agent to febrile patients 11%
I only give broad anti-bacterial agent if CRP or PCT are high 4.2%
I only give broad anti-bacterials to patients with structural lung diseases 35.8%
I never give broad anti-bacterial agent in severe viral infections 3.7%
5. Regarding initial anti-viral therapy, several options are possible
The level of evidence is so low that there is nothing I can give 48.9%
I prescribe (hydroxy)chloroquine 42.7%
I prescribe lopinavir/ritonavir 17.0%
I prescribe remdesivir 15%
I prescribe another anti-viral drug 4.6%
6. Are you starting an anti-inflammatory therapy?
No 52.4%
Yes IL-1 or IL-6 blockade 24.8%
Yes, complement blockade 1.4%
Yes, steroids 31.5%
Yes, another anti-inflammatory drug 2.4%
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(IQR) number of ICU beds was increased from 20
(11–36) to 35 (20–60) during the pandemic surge.
As the patient had 88 (peripheral oxygen saturation)
SpO2 on 9 l/min of oxygen, direct ICU admission was
reported in 56% (30–90%) of the respondents, with
significant variation across regions (Fig. 1, P < 0.0001).
Most intensivists not directly admitting patients to
the ICU would admit them to an intermediate care
unit managed by intensivists. However, the issue of
bed availability was reported in South Europe (4.5%),
South America (2.9%), Scandinavia (1.6%), Middle
Europe (1.6%), and the UK (1.1%). Should the patient
be not admitted to the ICU, a rapid response team
would be involved in 29% of the cases, the ICU spe-
cialist would make the outreach her/himself in 24% of
the cases, or an ICU nurse would be involved in 7%
of the cases. In all other cases, ward or ED physicians
would manage the patients. Direct ICU admission was
significantly associated with baseline number of ICU
beds (22 [12–40] vs. 18 [10–30] beds, P < 0.0001) and
with the number of COVID-19 patients managed (30
[11–52] vs. 38 [20–70] patients, P = 0.001), as well as
with management of patients in large cities (56.9% vs.
49.6%, P = 0.04).
Respondents were then asked about the first-line
oxygenation strategy, which varied significantly across
regions (Fig. 2, P < 0.0001). First-line high flow nasal
cannula (HFNC) was used by 22.9% of the respon-
dents (0% in Australia-New Zealand, 38% in Eastern
Europe). Noninvasive ventilation was used by 25.5%
of the respondents (5.4% in North America, 43.6% in
the UK). Interestingly, 8% of the respondents were
using first-line intubation (0% in Australia-New Zea-
land, 23% in Asia). Women less frequently initiated
HFNC (32% vs. 42%, P = 0.02). The availability of an
intermediate care unit influenced the use of HFNC or
non-invasive ventilation (NIV) (32.8% vs. 21.7%, P =
0.03). Along this line, a higher number of ICU beds
(24 (12–40) vs. 18 (10–30) beds, P = 0.0009) was asso-
ciated with the use of HFNC and NIV. Interestingly,
37.5% were using prone positioning in awake non-
ventilated patients. To assess whether HFNC or NIV
should be continued, ICU specialists relied on SpO2
(85.7%), respiratory rate (71.4%), followed by dyspnea
(47.1%), and comfort (45.4%). Criteria for intubation
included clinical signs of respiratory distress (94%),
high oxygen flow to maintain a SpO2 of 95% (33.5%),
or low SpO2 only (25.6%).
Fig. 1 World map displaying practice variations across regions regarding direct admission to the ICU or the intermediate care unit
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Following intubation, the patient had a partial
pressure of oxygen/fraction of inspired oxygen (P/F)
ratio of 84 mmHg. Although prone positioning
(71.2%) and neuromuscular blockade (59.7%) were
often used to optimize oxygenation, the practice
varied significantly across countries. For instance,
prone positioning was performed in 70–85% of the
cases in Asia, India, Eastern Europe, Middle Europe,
South America, South Europe, and the UK, whereas
Africa, Australia-New Zealand, Middle East, North
America, and Scandinavia were in the 50–70% range
(Fig. 3, P < 0.0001). Respondent’s age was associated
with the use of prone positioning (46 [39–54] vs. 44
[37–51] years, P = 0.007). Older respondent’s age (45
[37–52] vs. 47 [40–55] years, P = 0.0001), living in a
large city (54.2% vs. 46.8%, P = 0.03), and a higher
number of COVID-19 patients managed (35 [15–65]
vs. 30 [12–55] patients, P = 0.02) were associated
with the use of neuromuscular blockade.
Antibiotic prescribing was routine for all patients
in 44.2% of the respondents and biomarker-guided in
36.5%, without significant variation across regions.
Routine antibiotics were more frequently used by
respondents working in university-affiliated hospitals
(48.3% vs. 40.9%, P = 0.03) and those living in large
cities (49.3% vs. 40.2%, P = 0.01). Biomarker-guided
antibiotic therapy was less frequent in large cities
(47.3% vs. 57.4%, P = 0.007). Regarding antiviral
therapy, 48.9% reported not prescribing antivirals,
42.6% were giving hydroxychloroquine, 17%
lopinavir-ritonavir, and 15% remdesivir. Figure 4 dis-
plays significant variation in antiviral prescriptions
across regions (P < 0.0001). Physicians not prescrib-
ing antivirals were older (47 [40–54] vs. 44 [37–51]
years, P < 0.0001), and more frequently men (55.4%
vs. 39.9%, P < 0.0001). Conversely, those prescribing
hydroxychloroquine were younger (43 [37–50] vs. 47
[40–54] years, P < 0.0001), and more frequently
Fig. 2 World map displaying practice variations across regions regarding the use of noninvasive oxygenation strategies
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women (41.7% vs. 28.2%, P < 0.0001). There was
significant variation in the use of interleukin-6 (IL-
6)/IL-1 blockade or of corticosteroids across
countries (P < 0.0001 for both tests). Other collected
variables were not associated with the use of anti-
inflammatory drugs.
Discussion
This survey highlights important practice variations
in the management of severe COVID-19 patients,
including differences at regional and individual
levels. This illustrates that neither IDSA nor Surviv-
ing Sepsis Guidelines did recommend any of these
treatments, but instead encouraged inclusion of pa-
tients into trials [1, 4, 5]. Since the publication of
these guidelines, no more evidence has been made
available to ascertain that these specific COVID-19
therapies should be included in the standard of
care. Learning from this heterogeneity will not only
raise hypothesis on optimal patient’s management,
but also serves as a tool to suggest personalized
management for each clinical phenotype [6, 7].
This study has several limitations. First, the study
suffers from a nonresponse bias of 80%. Second,
even though only physicians have responded, we
cannot ascertain that all of them had the clinical ex-
pertise and the experience of managing COVID-19
patients. Last, questions about specific treatments
did not take into account the fact that the level of
evidence has changed over time.
Conclusion
As no management guidelines have allowed to
guide practices for the COVID-19 pandemic,
heterogeneous behaviors are reported. Large
Fig. 3 World map displaying practice variations across regions regarding the use of neuromuscular blockades and prone positioning
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outcome studies based on multinational registries
are warranted.
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